

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

**APPOINTMENT OF JOINT COMPANY SECRETARY
AND
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17
OF THE LISTING RULES**

APPOINTMENT OF JOINT COMPANY SECRETARY

The board (the “**Board**”) of directors (the “**Directors**”) of HBM Holdings Limited (the “**Company**”) hereby announces that, the Company convened board meeting on June 8, 2021 (the “**Board Meeting**”) and all the Directors of the Company considered and approved, among others, the appointment of Mr. Richard Yu Fu (傅裕) (“**Mr. Fu**”) as a joint company secretary of the Company, with effect from July 13, 2021. Mr. Wing Yat Christopher Lui (“**Mr. Lui**”), the current company secretary of the Company, will be the other joint company secretary of the Company.

The biographical details of Mr. Fu are set out below:

Mr. Richard Yu Fu, aged 29, joined the Group in August 2020 as its senior manager of investor relations and has been responsible for the investor relationship and Hong Kong listing related secretarial work of the Group since then. Mr. Fu is qualified as a lawyer and a securities practitioner in the People’s Republic of China and has extensive experience in corporate practice. Mr. Fu served as a trainee and lawyer in Jiangsu Fadeyongheng Law Firm (江蘇法德永衡律師事務所) from June 2014 to November 2015, and worked at the legal department of Juneyao Air (吉祥航空) from January 2016 to November 2016. From December 2016 to June 2018, Mr. Fu served as a supervisor of the vetting department and the secretary of the registration approval commission of the Shanghai Equity Exchange (上海股權託管交易中心), where he was mainly responsible for vetting applications for listing, non-public offering and significant equity restructuring. From March 2019 to August 2020, he was a joint company secretary of China Pioneer Pharma Holdings Limited (HKEX: 1345).

Mr. Fu graduated from the Nanjing University of Aeronautics and Astronautics (南京航空航天大學) with a bachelor’s degree in law in June 2014.

The biographical details of Mr. Lui are set out below:

Mr. Wing Yat Christopher Lui, aged 32, has over nine years of experience in the corporate secretarial field. He has worked for Tricor Services Limited since October 2011. He has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Mr. Lui is currently the joint named company secretary of TOT BIOPHARM International Company Limited (HKEX: 1875) and named company secretary of CARsgen Therapeutics Holdings Limited (HKEX: 2171). He was also the named company secretary of Brainhole Technology Limited (HKEX: 2203) from June 2018 to March 2020.

Mr. Lui received his bachelor's degree of science in economics and statistics from University College London in the United Kingdom in August 2011. He became a chartered secretary and an associate of both the Hong Kong Institute of Chartered Secretaries and the Chartered Governance Institute (formerly the Institute of Chartered Secretaries and Administrators) in the United Kingdom in 2017.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rule 8.17 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), a listed issuer must appoint a company secretary who meets the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that a listed issuer must appoint as its company secretary an individual who, in the opinion of the Stock Exchange, is capable of discharging the functions of company secretary of the listed issuer by virtue of his/her academic or professional qualifications or relevant experience. Mr. Fu currently does not possess the qualifications of company secretary as required under Rules 3.28 and 8.17 of the Listing Rules. Following the appointment of Mr. Fu, Mr. Lui, the current company secretary of the Company who possesses the requisite qualification and experience of a company secretary as required under Rules 3.28 and 8.17 of the Listing Rules, will act as the other joint company secretary of the Company. Mr. Fu and Mr. Lui, as joint company secretaries, will jointly discharge the duties and responsibilities of a company secretary.

In relation to the appointment of Mr. Fu as a joint company secretary of the Company, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period of three years from the date of Mr. Fu's appointment as a joint company secretary of the Company (the “**Waiver Period**”) on the grounds that the Company will engage Mr. Lui, the other joint company secretary of the Company who possesses the relevant professional qualifications of company secretary required under Rules 3.28 and 8.17 of the Listing Rules, to provide assistance and guidance to Mr. Fu in discharging his duties as one of the joint company secretaries of the Company.

This waiver is granted on the conditions that (i) Mr. Fu will be assisted by Mr. Lui during the Waiver Period; (ii) the waiver could be revoked if there are material breaches of the Listing Rules by the Company. The Stock Exchange expects that, after the end of the Waiver Period, the Company will be able to demonstrate that Mr. Fu can satisfy Rule 3.28 of the Listing Rules, after having the benefit of Mr. Lui's assistance, such that a further waiver will not be necessary; and (iii) the Company will announce the details of this waiver, including its reasons, details and conditions. The Company should seek the Stock Exchange's confirmation in this regard before the end of the Waiver Period.

The Board would like to extend its warm welcome to Mr. Fu on his new appointment.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, July 13, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Mai-Jing Liao as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.